|
| |
NAP1;3
| Symbol: | NAP1;3 | | Name(s): | NAP1;3 (NUCLEOSOME ASSEMBLY PROTEIN1;3); DNA binding | | Type: | protein-coding | | Organism: | Arabidopsis thaliana | | Synonyms: | MHM17.6, MHM17_6, NUCLEOSOME ASSEMBLY PROTEIN1;3 | | Links: |
Pubmed,
Entrez Gene,
Map Viewer.
|
Press Releases on NAP1;3:
|
 |
| Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection |
12th November, 2009 |
Optimer Pharmaceuticals, Inc. |
SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has completed enrollment in the second of two pivotal Phase 3 clinical
|
| Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI |
2nd June, 2009 |
Optimer Pharmaceuticals, Inc. |
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that additional results from its North American Phase 3 clinical study of fidaxomicin in patients
|
| Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection |
17th May, 2009 |
Optimer Pharmaceuticals, Inc. |
Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland
|
| BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections |
12th January, 2009 |
BD-Becton Dickinson |
SAN DIEGO, Jan. 12 /PRNewswire-FirstCall/ -- BD Diagnostics, a segment of
BD (Becton, Dickinson and Company) (NYSE: BDX), announced today it has
received clearance from the U.S. Food and Drug
|
| BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections |
7th July, 2008 |
|
SAN DIEGO, July 7 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE:
BDX), announced today the CE marking of the BD GeneOhm(TM) Cdiff molecular
assay for the
|
NAP1;3 results (if any) from reagent suppliers | 
|
C-Nap1 siRNA (h) sc-72669
C-Nap1 siRNA, shRNA and Lentiviral Particle Gene Silencers ... Delivery Time: 3- 5 business days ... C-Nap1 shRNA Plasmid (h), sc-72669-SH, 20 µg ...
http://www.scbt.com/datasheet-72669-c-nap1-sirna-h.html...
|
 |
Antibodies available - Antibodies | Imgenex
IMG-5900A, TAK1 binding protein 3 (TAB3), MGC45404, NF-kappa-B-activating protein 1 (NAP1), TAK1 binding protein 3 (TAB3), MAP kinase kinase kinase 7 ...
http://www.imgenex.com/alphabetic_antibody_list.php?key=T&do...
|
 |
Human IL-8/NAP-1 Instant ELISA BMS204/3INSTCE
3 Principles of the Test. An anti-human IL-8/NAP-1 coating antibody is adsorbed onto microwells. Human IL-. 8/NAP-1 present in the sample or standard ...
http://www.bendermedsystems.com/bm_products/MAN/204-3INSTCE....
|
 |
Purified Anti-Ninein Antibody - BioLegend
3. Matsumoto, T.,et al. 2008. Arterisocler Thromb Vasc Biol.10:1161. ... Ninein has also been shown to interact with CEP250/c-Nap1, CEP110, γ-tubulin, ...
http://www.biolegend.com/purified-anti-ninein-antibody-2038....
|
 |
TAB3 Bethyl Laboratories
TAK1-binding protein 3 (TAB3) is a binding and regulatory subunit of the transforming growth ... protein 3, MAP3K7IP3, NF-kappaB-activating protein 1,
and NAP1.
http://www.bethyl.com/category/TAB3/Antibody/AAAAAAAAGAAN...
|
 |
Chemokine Nomenclature - R&D Systems
CCL19, SCYA19, MIP-3 beta, ELC, Exodus-3, Ck beta 11, MIP-3 beta, ELC, Exodus-3, Ck beta 11, CCR7 ... CXCL8, SCYB8, IL-8, NAP-1, MDNCF, GCP-1, CXCR1, CXCR2 ...
http://www.rndsystems.com/chemokine_nomenclature.aspx...
|
 |
Anti-ABI1 (A5106) - Data Sheet
are members of a family of proteins that use the Arp2/3 complex to stimulate actin polymerization and ... WAVE-ABI1-Nap1-PIR121 complex.4-6 ABI1 has been ...
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Datashee...
|
 |
Search Bioportfolio and other Life Science Sites for NAP1;3,
or search for NAP1;3 on BioPortfolio's antibody search engine.
This page has been viewed 86 times
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
